2015 Volume 4 Issue 3 Pages 13-19
Purpose: To examine the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin in patients with diabetes undergoing hemodialysis.Subjects and Methods: A total of 16 patients with diabetes undergoing maintenance hemodialysis patients (an initial treatment group of receiving a DPP-4 inhibitor [n=9] and a changeover from alogliptin group [n=7]) were treated with teneligliptin (20 mg once a day) for more than 3 months, and the efficacy and safety were determined. Results: In the initial treatment group of receiving a DPP-4 inhibitor (6 patients received teneligliptin alone and 3 received supplementation with mitiglinide), the plasma glucose before hemodialysis (PG) and glycated albumin (GA) levels significantly decreased after the administration of teneligliptin for 3 months (PG decreased from 185±44 mg/dL to 153±28 mg/dL, p<0.05; GA decreased from 23.4±3.8% to 19.7±3.0?, p<0.01). The proportion of patients having good glycemic control of less than 20% of the GA levels significantly increased from 11.1% to 55.6% （p<0.05）after the administration of teneligliptin for 3 months. In the changeover from alogliptin group the PG and GA levels did not change significantly after the administration of teneligliptin for 3 months. No adverse events or hypoglycemia was observed during the observation period.Conclusion: Teneligliptin is an effective and safe drug for hemodialysis patients. The hypoglycemic effect of 20 mg of teneligliptin is approximately equivalent to that of 6.25 mg of alogliptin.
